Crescita Therpeutc (TSE:CTX) has released an update.
Crescita Therapeutics Inc. reported increased first quarter revenues in 2024, rising to $4,996 from $4,602 in the previous year, while facing a decline in gross profit and adjusted EBITDA. The company showed strong commercial focus in its Skincare segment, driven by the ART FILLER launch and online sales growth, and is working towards a new U.S. partnership and international launches for its Pliaglis product. Despite a challenging quarter, Crescita remains optimistic about its growth opportunities and returning to profitability, backed by a solid balance sheet and strategic developments.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.
